Company Encyclopedia
View More
name
Alumis
ALMS.US
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company’s clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc.
4.513 T
ALMS.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking72/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-66.88%E
    • Profit Margin-1108.24%E
    • Gross Margin100.00%A
  • Growth ScoreC
    • Revenue YoY0.00%C
    • Net Profit YoY-2.67%C
    • Total Assets YoY18.29%A
    • Net Assets YoY10.44%B
  • Cash ScoreD
    • Cash Flow Margin-9.02%D
    • OCF YoY0.00%C
  • Operating ScoreE
    • Turnover0.05E
  • Debt ScoreA
    • Gearing Ratio21.16%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Dir Akkaraju Buys 262,027 ($2M) Of Alumis Inc [ALMS]

    Akkaraju Srinivas Director of Alumis Inc [ALMS] filed a Form 4 on December 4, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/2/25-12/4/25TransactionPurchaseShares262,027Price$7.79Value$2,039,880Ending Holdings: 5,570,607 - IndirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    ALMS
    +33.98%
    Reuters·
    US
    ALMS
    +33.98%

    Alumis Inc. unveils late-stage immunology pipeline and key upcoming clinical milestones

    Alumis Inc. has unveiled its late-stage precision immunology pipeline, featuring three clinical-stage molecules: Envudeucitinib for psoriasis and SLE, A-005 for multiple sclerosis, and Lonigutamab for thyroid eye disease. Key milestones include Phase 3 data for Envudeucitinib in early Q1 2026 and Phase 2b data in SLE by Q3 2026. The company had $377.7 million in cash as of September 30, 2025, to fund operations into 2027.

    Reuters·
    US
    ALMS
    +33.98%
    Reuters·
    US
    ALMS
    +33.98%

    Foresite Labs Reports Acquisition of Alumis Inc. Common Shares

    Foresite Labs, LLC and Foresite Labs Affiliates 2021, LLC have acquired common shares of Alumis Inc., as reported in a filing accessible via EDGAR. This acquisition involves significant beneficial owners and other reporting beneficial owners. The original content was published by Alumis Inc. on November 25, 2025, via the U.S. SEC's EDGAR system.

    Reuters·
    US
    ALMS
    +33.98%
    Reuters·
    US
    ALMS
    +33.98%

    Dir Akkaraju Buys 125,743 ($905.3K) Of Alumis Inc [ALMS]

    Akkaraju Srinivas Director of Alumis Inc [ALMS] filed a Form 4 on November 24, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/20/25TransactionPurchaseShares125,743Price$7.20Value$905,350Ending Holdings: 5,134,991 - IndirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    ALMS
    +33.98%
    Reuters·
    US
    ALMS
    +33.98%

    Alumis (NASDAQ:ALMS) Trading 11.3% Higher Following Insider Buying Activity

    Alumis Inc. (NASDAQ:ALMS) saw its stock rise by 11.3% following insider buying activity. Director Srinivas Akkaraju purchased significant shares, increasing his ownership by over 36%. Director James B. Tananbaum also acquired shares, boosting his stake by 8.10%. Despite the stock's rise, analyst ratings are mixed, with some downgrades and a consensus target price of $19.20. The company's recent earnings missed expectations, and several institutional investors have modified their holdings in Alumis.

    Market Beat·
    US
    ALMS
    +33.98%
    Market Beat·
    US
    ALMS
    +33.98%
    © 2025 Longbridge｜Disclaimer